First-year progress in MD Anderson’s Moon Shots Program

submitted by: mdanderson
The University of Texas MD Anderson Cancer Center in September 2012 announced its Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. The program initially targets acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung cancer; melanoma; prostate cancer; and triple-negative breast and high-grade serious ovarian cancers....

Ovarian cancer screening with simple blood test

submitted by: mdanderson
Download from iTunes: https://itunes.apple.com/us/itunes-u/ovarian-cancer-screening-simple/id4... A simple blood test currently approved to detect ovarian cancer disease recurrence is full of new possibility. It may, one day, detect invasive, high-grade disease at its earliest, most curable stage. Listen to Karen Lu, M.D., professor and chair of Gynecologic Oncology and Reproductive Medicine, as she details the findings, and what they could, one day, mean for women.

UT MD Anderson Cancer Center launches unprecedented Moon Shots Program to increase patient survival during the next decade

submitted by: mdanderson
Inspired by America’s drive a generation ago to put a man on the moon, MD Anderson’s Moon Shots Program is a highly-concentrated effort to rapidly and dramatically decrease suffering and death in several major cancers, including acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung; melanoma; prostate and two cancers linked at the molecular level: triple-negative breast and ovarian. Focused teams are building on new technology and...

Ovarian Cancer Research

submitted by: mdanderson

Anil Sood, M.D., discusses research connecting high platelet counts to the severity of ovarian cancer and the Sprint for Life, which raises funds for the Blanton-Davis Ovarian Cancer Research Program.

http://bit.ly/IF7tMG

How Drosha and Dicer work in RNA interference

submitted by: mdanderson

Animated demonstration on how Dicer and Drosha work in RNA interference.

Dream Team targets molecular factors common in women's cancers

submitted by: mdanderson

First clinical trials begin soon to test new drugs against ovarian, endometrial and breast cancers that harbor dysfunctional PI3K pathways. MD Anderson's Gordon Mills explains.